Biotech News

Bolt Biotherapeutics to Participate in Upcoming Conferences

Bolt Biotherapeutics (BOLT)Bolt BiotherapeuticsConference / presentation

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences.

Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt and Co-Founder and former Chief Executive Officer of Prana Therapies, will deliver a company presentation, followed by a fireside chat, on Tuesday, November 10, 2026, at 10:40 a.m. ET at the Stifel 2026 Healthcare Conference , and attend Jefferies Global Healthcare Conference in London , taking place November 16–19, 2026.

Related news

Bolt Biotherapeutics

Immune-Stimulating Antibody Conjugates Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates that combine tumor targeting with activation of innate and adaptive immunity. BDC-4182 BDC-4182 targets claudin 18.2 and is being evaluated in gastric, gastroesophageal junction, pancreatic, and other solid...

Recent company news

Stock data

Close
5.06 USD
Market cap
9.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States